NPM1 and myelodysplastic syndrome: Mild cytotoxic effects were detected in the rest of the AML and MDS-AML samples, AML7 to 9, classified as AML with NPM1 mutant or inv(16)/CBFB-MYH11 and favorable risk, and AML 10, a TP53 mutant AML (Figure 6A,C).